What Happened?
South San Francisco, CA-based Senti-Bio Appointed Deborah Knobelman as Chief Financial Officer
About the Company
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.
About the Person
Deborah Knobelman is Chief Financial Officer at Senti Bio. Previously, Deborah held various senior HR leadership roles in the industry.
Info Source
News
Short Profile